Q-omics provides the consensus-scored RPL31P57 profile across patient tissues and cancer cell-line models. RPL31P57 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL31P57 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, RPL31P57 RNA expression shows 6,102 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUSC, and STAD as cancer lineages where RPL31P57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL31P57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL31P57 survival associations across molecular data types. RPL31P57 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL31P57 RNA expression–survival associations across cancer types. High RPL31P57 expression shows unfavorable associations in DLBC, UVM, BLCA, LUAD and UCEC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL31P57 RNA expression.
This table summarizes RPL31P57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL31P57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL31P57 shows lower tumor expression in LUSC, LUAD and THCA. The LUSC box plot shows higher RPL31P57 RNA expression in normal versus tumor tissue (log2 FC = −0.091, t-test p < 0.001).
This table shows molecular features associated with RPL31P57 in patient tissues and cancer cell lines. In patient samples, RPL31P57 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
